Molecular IP
Intellectual Property for Life Sciences, Chemistry and Biotechnology

By Joseph P. Mathew Practitioners have another tool at their disposal in combating 103 rejections. The Court of Appeals for the Federal Circuit (CAFC) vacated a decision of the Patent… read more

In an update to Steven M. Kellner’s Molecular IP post, CRISPR: The Biotechnology Dispute of This Century, the United States Patent Trial and Appeal Board (PTAB) has come down on… read more

By Neil C. Maskeri The Biologics Price Competition and Innovation Act of 2009 (BPCIA) established an abbreviated approval process for biosimilar applications.  Subsection (k) of the BPCIA allows the submission… read more

By Robert D. Leonard On December 15, 2016, Idenix Pharmaceuticals LLC, a subsidiary of Merck & Co., was awarded $2.54 billion for infringement of its hepatitis C virus (HCV) treatment… read more